Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of paclitaxel polymeric micelles and fruquintinib. Paclitaxel polymeric micelles is a novel formulation of paclitaxel that uses polymeric micelles as a delivery system, eliminating the need for polyoxyethylene castor oil solvent and pretreatment with anti-allergy medications. Fruquintinib is an oral, highly selective VEGFR 1/2/3 inhibitor. This combination has shown promising efficacy in the treatment of advanced gastric cancer and gastroesophageal junction adenocarcinoma as second-line therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paclitaxel polymeric micelles + fruquintinib.